Cabazitaxel Sanofi Ástralía - enska - Department of Health (Therapeutic Goods Administration)

cabazitaxel sanofi

sanofi-aventis australia pty ltd - cabazitaxel acetone solvate; cabazitaxel -

Risedronate Sanofi-Aventis Ástralía - enska - Department of Health (Therapeutic Goods Administration)

risedronate sanofi-aventis

sanofi-aventis australia pty ltd - risedronate sodium; calcium carbonate; colecalciferol; cholecalciferol -

Risedronate Sanofi-Aventis Combi D Ástralía - enska - Department of Health (Therapeutic Goods Administration)

risedronate sanofi-aventis combi d

sanofi-aventis australia pty ltd - risedronate sodium; calcium carbonate; colecalciferol; cholecalciferol -

Nature's Own Zinc + C Chewable Ástralía - enska - Department of Health (Therapeutic Goods Administration)

nature's own zinc + c chewable

sanofi-aventis healthcare pty ltd t/a sanofi consumer healthcare - sodium ascorbate, quantity: 112.5 mg (equivalent: ascorbic acid, qty 100 mg); ascorbic acid, quantity: 150 mg; zinc gluconate, quantity: 45 mg (equivalent: zinc, qty 6.5 mg) - tablet, chewable - excipient ingredients: hypromellose; magnesium stearate; maize starch; glucose monohydrate; microcrystalline cellulose; sucralose; silicon dioxide; maltodextrin; ascorbic acid; purified water; acacia; soya oil; dunaliella salina; citric acid; sucrose; mixed (low-alpha type) tocopherols concentrate; flavour - maintain/support collagen formation ; maintain/support healthy immune system function ; decrease/reduce/relieve common cold duration ; decrease/reduce/relieve the severity of common cold symptoms ; maintain/support skin health ; maintain/support wound healing

Evoltra Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

evoltra

sanofi-aventis new zealand limited - clofarabine 20mg;   - concentrate for injection - 20 mg/20ml - active: clofarabine 20mg   excipient: sodium chloride water for injection - evoltra® is indicated for treatment of acute lymphocytic leukaemia (all) in paediatric patients who have relapsed or are refractory after receiving at least two prior regimens.